Abstract |
IMVAMUNE is a Modified Vaccinia Ankara (MVA)-based virus that is being developed as a safer 3rd generation smallpox vaccine. In order to determine the optimal dose for further development, a double-blind, randomized Phase II trial was performed testing three different doses of IMVAMUNE in 164 healthy volunteers. All three IMVAMUNE doses displayed a favourable safety profile, with local reactions as the most frequent observation. The 1 x 10(8)TCID(50) IMVAMUNE dose induced a total antibody response in 94% of the subjects following the first vaccination and the highest peak seroconversion rates by ELISA (100%) and PRNT (71%). This IMVAMUNE dose was considered to be optimal for the further clinical development of this highly attenuated poxvirus as a safer smallpox vaccine.
|
Authors | Alfred von Krempelhuber, Jens Vollmar, Rolf Pokorny, Petra Rapp, Niels Wulff, Barbara Petzold, Amanda Handley, Lyn Mateo, Henriette Siersbol, Herwig Kollaritsch, Paul Chaplin |
Journal | Vaccine
(Vaccine)
Vol. 28
Issue 5
Pg. 1209-16
(Feb 03 2010)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 19944151
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Copyright | (c) 2009 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Viral
- Smallpox Vaccine
- Vaccines, Attenuated
- imvamune
|
Topics |
- Adult
- Antibodies, Viral
(blood, immunology)
- Dose-Response Relationship, Immunologic
- Double-Blind Method
- Female
- Humans
- Male
- Safety
- Smallpox
(blood, immunology, prevention & control)
- Smallpox Vaccine
(administration & dosage, immunology)
- Vaccines, Attenuated
(administration & dosage, immunology)
|